FK506 reduces infarct volume due to permanent focal cerebral ischemia by maintaining BAD turnover and inhibiting cytochrome c release.
D000704:Analysis of Variance; D000818:Animals; D015153:Blotting, Western / Q000379:methods; D020520:Brain Infarction / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D002352:Carrier Proteins / Q000378:metabolism*; D045304:Cytochromes c / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D007150:Immunohistochemistry / Q000379:methods; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D020244:Infarction, Middle Cerebral Artery / Q000150:complications / Q000188:drug therapy; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D019579:Neocortex / Q000378:metabolism / Q000473:pathology; D010766:Phosphorylation; D016559:Tacrolimus / Q000627:therapeutic use*; D013778:Tetrazolium Salts; D013997:Time Factors; D051025:bcl-Associated Death Protein
C494820:Bad protein, mouse; D002352:Carrier Proteins; D007166:Immunosuppressive Agents; D013778:Tetrazolium Salts; D051025:bcl-Associated Death Protein; C009591:triphenyltetrazolium; D045304:Cytochromes c; D016559:Tacrolimus